• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Endologix CEO McDermott to step down; shares slide -10% on Q4 results | Personnel Moves for Feb. 22, 2018

Endologix CEO McDermott to step down; shares slide -10% on Q4 results | Personnel Moves for Feb. 22, 2018

February 22, 2018 By Brad Perriello

Endologix CEO John McDermott to step downEndologix (NSDQ:ELGX) CEO John McDermott is planning to step down once an appropriate replacement is found, the company said yesterday as it announced fourth-quarter results that handily topped earnings expectations but missed on the top line.

“Despite the business challenges over the past couple of years, I am confident that Endologix has a bright future. Our vision is clear, the value proposition is compelling, and our pipeline of new products positions us for significant long-term growth. I remain deeply committed to our employees, physicians, and patients and will do whatever I can to support an effective leadership transition,” McDermott said in prepared remarks.

“On behalf of the board of directors and the entire Endologix team, I would like to thank John for his remarkable passion and dedication to our company. His leadership has been critical in positioning Endologix as an innovative market leader and in bringing novel solutions to doctors and patients across the globe. We appreciate John’s continued involvement and support of the company, and we wish him well in his future endeavors,” added chairman Daniel Lemaitre.

Fourth-quarter earnings surprise despite sales miss

Endologix pared its losses to -$14.5 million, or -17¢ per share, on sales of $44.0 million for the three months ended Dec. 31, 2017, down -41.7% despite a -7.3% sales decline compared with Q4 2016.

Adjusted EPS came in at -8¢, bettering the consensus by 12¢; analysts on Wall Street were looking for sales of $44.9 million.

Full-year losses were down -58.0% to -$64.6 million, or -80¢ per share, on a -6.1% sales decline to $181.2 million compared with 2016.

“While our top-line performance during the fourth quarter finished at the low end of our guidance, we were pleased to have achieved expanded gross margins and to have further lowered our operating expenses,” McDermott said in a separate release. “Subsequent to the quarter end, we completed patient enrollment in the Elevate IDE clinical study. We plan to file regulatory submissions in the third quarter of 2018 and currently anticipate potential approval of the Alto device in both the U.S. and European markets in 2019. The Alto device incorporates several design enhancements that are intended to simplify the procedure and enable the system to treat a wider range of AAA anatomies than Ovation iX. We also welcomed Greg Morrow as our chief marketing officer, and we believe that under his leadership our team will be able to further strengthen our brand value proposition and maximize the impact of our innovative new product pipeline. Looking forward, we are confident that we have sufficient resources to drive innovation and position the Company for future growth in its addressable markets.”

Endologix said it expects to report losses per share of -89¢ to -95¢ this year on sales of $170 million to $180 million.

ELGX shares, which slid -10.5% to $ 3.92 apiece in pre-market trading, opened down -13.0% at $3.81 apiece before recovering somewhat to $3.93 per share in early trading.

 Attune Medical promotes COO Warner to CEO
Attune Medical (formerly known as Advanced Cooling Therapy) said it promoted COO Keith Warner to CEO and gave him a seat on the board.
Read more

 Dynatronics shuffles the deck
Dynatronics (NSDQ:DYNT) said it’s parting ways with co-founder, chairman & CEO Kelvyn Cullimore after 26 years and separating the chairman and CEO roles, with newly named chairwoman Erin Enright leading a replacement search that’s slated to end by June 30. The role of president will go unfilled after a realignment to create a therapy products division led by Brian Baker as president, the company said. In a separate release, Dynatronics announced the appointment effective today of Skyler Black to fill the newly created corporate controller position.
Read more

 Wound Management Technologies puts CFO Carmena in the corner office
Wound Management Technologies (OTC:WNDM) said it put CFO Michael Carmena in the corner office effective Feb. 20.
Read more

 Biocoat names Bracco Dx vet Moran as CEO
Biocoat said it named Bracco Diagnostics veteran Jim Moran to be its new president & CEO.
Read more

 Cardiovascular Systems gets Points for CFO
Cardiovascular Systems (NSDQ:CSII) said it promoted Jeff Points to CFO, succeeding Larry Betterley in a planned succession.
Read more

  • Presbia taps Lind for COO, Michna for CCO
  • Medtronic’s new fincom director is a Honeywell vet

Filed Under: MassDevice Earnings Roundup, Stent Grafts, Wall Street Beat Tagged With: attunemedical, Biocoat, Cardiovascular Systems Inc., Dynatronics Corp, Endologix, Medtronic, Personnel Moves, Presbia, Wound Management Technologies

More recent news

  • Medtronic earns CE mark for redo TAVI procedure
  • Natus Neuro launches BrainWatch AI-driven, point-of-care EEG
  • Boston Scientific has positive real-world Acurate Prime TAVI data
  • Johnson & Johnson MedTech launches ultrasound catheter for imaging in cardiac ablation procedures
  • Onward reports more successful BCI implants

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy